McMahon M M, Schwenk W F, Haymond M W, Rizza R A
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Diabetes. 1989 Jan;38(1):97-107. doi: 10.2337/diab.38.1.97.
Recent studies indicate that hydrogen-labeled glucose tracers underestimate glucose turnover in humans under conditions of high flux. The cause of this underestimation is unknown. To determine whether the error is time-, pool-, model-, or insulin-dependent, glucose turnover was measured simultaneously with [6-3H]-, [6,6-2H2]-, and [6-14C]glucose during a 7-h infusion of either insulin (1 mU.kg-1.min-1) or saline. During the insulin infusion, steady-state glucose turnover measured with both [6-3H]glucose (8.0 +/- 0.5 mg.kg-1.min-1) and [6,6-2H2]glucose (7.6 +/- 0.5 mg.kg-1.min-1) was lower (P less than .01) than either the glucose infusion rate required to maintain euglycemia (9.8 +/- 0.7 mg.kg-1.min-1) or glucose turnover determined with [6-14C]glucose and corrected for Cori cycle activity (9.8 +/- 0.7 mg.kg-1.min-1). Consequently "negative" glucose production rates (P less than .01) were obtained with either [6-3H]- or [6,6-2H2]- but not [6-14C]glucose. The difference between turnover estimated with [6-3H]glucose and actual glucose disposal (or 14C glucose flux) did not decrease with time and was not dependent on duration of isotope infusion. During saline infusion, estimates of glucose turnover were similar regardless of the glucose tracer used. High-performance liquid chromatography of the radioactive glucose tracer and plasma revealed the presence of a tritiated nonglucose contaminant. Although the contaminant represented only 1.5% of the radioactivity in the [6-3H]glucose infusate, its clearance was 10-fold less (P less than .001) than that of [6-3H]glucose. This resulted in accumulation in plasma, with the contaminant accounting for 16.6 +/- 2.09 and 10.8 +/- 0.9% of what customarily is assumed to be plasma glucose radioactivity during the insulin or saline infusion, respectively (P less than .01). When corrected for the presence of the contaminant, glucose turnover determined with [6-3H]glucose during insulin infusion (9.5 +/- 0.6 mg.kg-1.min-1) no longer differed from either the glucose infusion rate or that determined with [6-14C]glucose. Therefore, the underestimation of glucose turnover during insulin infusion and negative glucose production rates observed with traditional methods to analyze plasma radioactivity and commercially available tracers is the result of an artifactual increase in [6-3H]glucose specific activity. The etiology of the underestimation of glucose turnover with [6,6-2H2]glucose remains to be determined.
近期研究表明,在高代谢通量条件下,氢标记的葡萄糖示踪剂会低估人体中的葡萄糖周转率。这种低估的原因尚不清楚。为了确定该误差是否与时间、库、模型或胰岛素有关,在7小时内输注胰岛素(1 mU·kg⁻¹·min⁻¹)或生理盐水期间,同时用[6-³H]-、[6,6-²H₂]-和[6-¹⁴C]葡萄糖测量葡萄糖周转率。在输注胰岛素期间,用[6-³H]葡萄糖(8.0±0.5 mg·kg⁻¹·min⁻¹)和[6,6-²H₂]葡萄糖(7.6±0.5 mg·kg⁻¹·min⁻¹)测得的稳态葡萄糖周转率均低于维持血糖正常所需的葡萄糖输注速率(9.8±0.7 mg·kg⁻¹·min⁻¹)或用[6-¹⁴C]葡萄糖测定并校正了科里循环活性后的葡萄糖周转率(9.8±0.7 mg·kg⁻¹·min⁻¹)(P<0.01)。因此,用[6-³H]-或[6,6-²H₂]-葡萄糖可得出“负”葡萄糖生成率(P<0.01),而用[6-¹⁴C]葡萄糖则不会。用[6-³H]葡萄糖估算的周转率与实际葡萄糖处置(或¹⁴C葡萄糖通量)之间的差异不会随时间减小,且不依赖于同位素输注的持续时间。在输注生理盐水期间,无论使用哪种葡萄糖示踪剂,葡萄糖周转率的估算值都相似。对放射性葡萄糖示踪剂和血浆进行高效液相色谱分析发现存在一种含³H的非葡萄糖污染物。尽管该污染物仅占[6-³H]葡萄糖输注液中放射性的1.5%,但其清除率比[6-³H]葡萄糖低10倍(P<0.001)。这导致其在血浆中蓄积,在输注胰岛素或生理盐水期间,该污染物分别占通常假定为血浆葡萄糖放射性的16.6±2.09%和10.8±0.9%(P<0.01)。校正污染物的存在后,在输注胰岛素期间用[6-³H]葡萄糖测定的葡萄糖周转率(9.5±0.6 mg·kg⁻¹·min⁻¹)与葡萄糖输注速率或用[6-¹⁴C]葡萄糖测定的结果不再有差异。因此,用传统方法分析血浆放射性和市售示踪剂时,在输注胰岛素期间观察到的葡萄糖周转率低估和负葡萄糖生成率是[6-³H]葡萄糖比活度人为增加的结果。用[6,6-²H₂]葡萄糖低估葡萄糖周转率的病因仍有待确定。